Journal
IMMUNOLOGICAL REVIEWS
Volume 266, Issue 1, Pages 161-174Publisher
WILEY
DOI: 10.1111/imr.12310
Keywords
Ubc13; K63-polyubiquitylation; innate immunity; adaptive immunity
Categories
Funding
- Susan G. Komen for the Cure [KG111506]
- San Diego Cancer Council Collaborative Translational Grant - Pedal for the Cause San Diego
- NIH [CA163798, AI043477]
Ask authors/readers for more resources
Among all the E2 ubiquitin-conjugating enzymes, Ubc13, which heterodimerizes with Uev1a, specifically mediates lysine 63 (K63)-linked protein polyubiquitylation, a process that does not lead to proteasomal degradation of its substrates. Instead, it plays a key role in signal transduction. Numerous roles of Lys63-linked polyubiquitylation in immune responses have emerged, indicating the importance of this regulatory strategy. Here, we summarize some of the signaling pathways that depend on Lys63-linked polyubiquitylation during innate and adaptive immune responses, with a focus on the underlying molecular mechanisms. In addition, we describe how Ubc13 itself is regulated and outline its function in transforming growth factor signaling. We discuss the current progress in pharmacological targeting of Ubc13 in inflammatory and autoimmune diseases as well as cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available